{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:24:21Z","timestamp":1771237461139,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.atherosclerosis.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T22:41:41Z","timestamp":1610491301000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-1253","authenticated-orcid":false,"given":"Antonio J.","family":"Vallejo-Vaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris J.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.atherosclerosis.2021.01.003_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/clp.10.22","article-title":"Encouraging appropriate treatment for familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2010","journal-title":"Clin. Lipidol."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration","volume":"22","author":"Eas Familial Hypercholesterolaemia Studies Collaboration","year":"2016","journal-title":"Atherosclerosis Suppl."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","author":"Representatives of the Global Familial Hypercholesterolemia Community","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"9753","key":"10.1016\/j.atherosclerosis.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur. Heart J."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.01.003_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"issue":"8934","key":"10.1016\/j.atherosclerosis.2021.01.003_bib13","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.01.003_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0002-9149(93)90438-I","article-title":"Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and\/or previous myocardial infarction","volume":"71","author":"The Scandinavian Simvastatin Survival Study Group","year":"1993","journal-title":"Am. J. Cardiol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2021.01.003_bib16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.01.003_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2019.09.015","article-title":"First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated","volume":"290","author":"Stock","year":"2019","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2021.01.003_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9493","key":"10.1016\/j.atherosclerosis.2021.01.003_bib22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol treatment trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:27Z","timestamp":1762187127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":22,"alternative-id":["S0021915021000034"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.01.003","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}